AI tool to guide treatment choices for hard-to-treat cancers
Part of Cancer clinical trials.
This trial tests an AI (neural network) decision-support tool that uses genetic test results to help guide treatment decisions in people with advanced solid tumors. It may help doctors choose better next steps when standard treatment options are no longer available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 21 or older.
- You have a confirmed solid cancer diagnosis based on tumor tissue or fluid testing.
- You have genetic test results from a comprehensive NGS panel (from tumor or blood); if from blood, it must be done during the metastatic stage.
- Your health status is good enough for study visits (ECOG 0 to 2).
- Your cancer has progressed after prior treatment, and you have at least one measurable tumor spot on scans.
- You can likely live at least 12 weeks and have adequate blood, liver, and kidney function for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
This study tests an AI system that helps doctors find clinical trials for cancer patients whose disease has worsened. It uses electronic health records to suggest trial options, aiming to make it easier for patients to access new treatments.
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
This trial tests a non-invasive, AI-based monitoring program for people with solid tumors. It aims to help track how you’re doing during or after curative-intent treatment, using information collected without extra procedures.
This study tests whether a computer-based tool can help doctors make treatment decisions for stomach, colon, or rectal cancer. It compares the computer's suggestions with the recommendations of a team of cancer specialists.
This study tests how well an AI tool can guide which pre-surgery treatment is best for people with pancreatic cancer that can be removed. It uses your tumor's genetic fingerprint to choose the most effective therapy.
Hear when a new Solid Organ Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.